All Photos (2)

Health Discovery Corporation Inks Deal for Final Validation of a New Molecular Diagnostic Test for Colon Cancer (Business Wire)

SAVANNAH, Ga.----Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer.

StemCells, Inc. Announces First Human Neural Stem Cell Transplant in Landmark Myelination Disorder Trial (GlobeNewswire)

PALO ALTO, Calif. -- StemCells, Inc. announced today that its proprietary HuCNS-SC® human neural stem cells have been used to treat the first patient enrolled in its Phase I clinical trial in Pelizaeus-Merzbacher Disease , a myelination disorder that afflicts male children. The stem cells were administered yesterday at the University of California, San Francisco Children's Hospital by direct injection into the brain of a patient with connatal PMD, the most severe form of the disease. This marks the first time that neural stem cells have been transplanted as a potential treatment for a myelination disorder, and the second clinical trial involving the use of HuCNS-SC cells in a neurodegenerative disease. 

Capstone Therapeutics to Host Quarterly Update Conference Call (GlobeNewswire)

TEMPE, Ariz. -- Capstone Therapeutics , trade name of OrthoLogic Corp. will host a conference call and webcast on Wednesday, February 17, 2010 at 4:30pm EST / 3:30pm CST / 2:30pm MST / 1:30pm PST. The call may be accessed at 888-857-6932 , 719-457-2637 ; accompanying slides can be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning February 17, 2010 at 7:30pm EST until midnight February 20, 2010 and may be accessed at 888-203-1112 or 719-457-0820 with replay passcode 9579164.